直肠癌再程放疗采用笔束扫描质子治疗的单中心经验
单中心回顾性分析28例既往接受盆腔放疗的直肠癌患者,再程采用笔束扫描质子治疗(PBS-PT),中位再程剂量44.4 Gy,24例同步化疗。3例(10.7%)发生3级急性毒性,4例(14.2%)发生晚期<3级毒性(含1例5级)。1年局部进展率33.7%,无进展生存率45.0%,总生存率81.8%。
要点
- PBS-PT再程放疗急性3级毒性率10.7%,晚期<3级毒性率14.2%。
- 1年局部进展率33.7%,无进展生存率45.0%,总生存率81.8%。
- 中位再程剂量44.4 Gy,24/28例同步化疗,6例后续手术。
核心结论
- PBS-PT再程放疗在既往盆腔放疗的直肠癌患者中急性毒性低、晚期毒性可接受,可作为高危人群的治疗选择,需继续随访。
研究设计与样本
- 单中心、回顾性、经机构审查委员会批准的分析,纳入2016至2019年接受PBS-PT再程放疗的28例直肠癌且既往盆腔放疗患者。
主要发现
- 18例为复发直肠癌(中位既往剂量54.0 Gy),10例为原发直肠癌且既往放疗方案不一。
- 中位再程剂量44.4 Gy(范围16.0-60.0 Gy),21/28例每日两次,24/28例同步化疗,6例接受手术切除。
- 3例(10.7%)发生3级急性毒性,1例因毒性未完成放疗;4例(14.2%)发生晚期<3级毒性,含1例既往放疗相关损伤患者的5级毒性。
- 1年局部进展率33.7%(95%CI 14.5%-52.9%),无进展生存率45.0%(95%CI 26.2%-63.8%),总生存率81.8%(95%CI 67.3%-96.3%)。
临床怎么用
- 对于既往接受盆腔放疗的直肠癌患者,可考虑PBS-PT再程放疗,需关注急性及晚期毒性,尤其是既往放疗相关损伤者。
局限性
- 单中心回顾性研究,样本量小(28例),随访时间有限(中位28.6个月),需更长随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Reirradiation for rectal cancer (RC) after prior pelvic radiation therapy (RT) has been shown to be safe and effective. However, limited data exist for proton therapy (PT), including pencil beam scanning proton therapy (PBS-PT). We hypothesize that PT is safe and feasible for re-treatment and may allow for decreased toxicity and treatment escalation. METHODS AND MATERIALS: A single-institution, retrospective, institutional review board-approved analysis of all patients with RC and prior pelvic RT receiving PBS-PT reirradiation was performed. Data on patient and treatment characteristics and outcomes were collected. Local progression, progression-free survival, overall survival, and late grade >3 toxicity were estimated using the Kaplan-Meier method. RESULTS: Twenty-eight patients (median follow-up: 28.6 months) received PBS-PT reirradiation between 2016 and 2019, including 18 patients with recurrent RC (median prior dose: 54.0 Gy) and 10 patients with de novo RC and variable prior RT. The median reirradiation dose was 44.4 Gy (range, 16.0-60.0 Gy; 21 of 28 twice daily), and 24 of 28 patients received concurrent chemotherapy. Six underwent surgical resection. Three (10.7%) experienced grade 3 acute toxicities, and 1 did not complete RT owing to toxicity. Four (14.2%) had late grade <3 toxicity, including 1 grade 5 toxicity in a patient with a prior RT-related injury. The 1-year local progression, progression-free survival, and overall survival rates were 33.7% (95% confidence interval [CI], 14.5%-52.9%), 45.0% (95% CI, 26.2%-63.8%), and 81.8% (95% CI, 67.3%-96.3%), respectively. CONCLUSIONS: This is the largest series using PT for reirradiation for RC and the first study using PBS-PT. Low acute toxicity rates and acceptable late toxicity support PBS-PT as an option for this high-risk patient population, with a need for continued follow-up.
引用
- Koroulakis A, Molitoris J, Kaiser A, et al. Reirradiation for Rectal Cancer Using Pencil Beam Scanning Proton Therapy: A Single Institutional Experience. Adv Radiat Oncol. 2020. PMID: 33490730. doi:10.1016/j.adro.2020.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。